IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Aisling Capital Management LP

Q2 2020 Holdings

Filed 2020-08-10 | 13 holdings | $131.3M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
BridgeBio (Bbio)(BBIO)COM10806X102$130.1M3,989,41299.1%
Aclaris Theraputics Inc (Acrs)(ACRS)COM00461U105$1.0M634,4550.8%
Eidos Therapeutics, Inc. (Eidix)(EIDXGBP)COM28249H104$53.6K1,123,6300.0%
Avrobio, Inc. (Avro)COM05455M100$17.6K1,009,7790.0%
Aeglea Biotherapeutics Inc (Agle)(AGLEUSD)COM00773J103$15.6K1,691,1510.0%
Syndax Pharmaceuticals Inc. (Sndx)(SNDX)COM87164F105$15.2K1,025,0000.0%
Atreca (Bcel)(BCELUSD)CL A COM04965G109$8.2K387,6530.0%
ObsEva SA (Obsv)COMH5861P103$8.2K1,386,3380.0%
Marker Therapeutics, Inc. (Mrkr)COM57055L107$4.1K2,000,0000.0%
Sunesis Pharmaceuticals, Inc. (Snss)COM867328700$2.7K10,100,0000.0%
Zosano Pharma Corporation (Zsan)COM98979H202$2.3K2,718,2260.0%
Verona Pharma plc (Vrna)(VRNA)COM925050106$2.1K443,5960.0%
Nabriva Therapeutics plc (Nbrv)SHSG63637105$1.3K1,910,2870.0%